• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

Zontivity Launch Meeting

















Measure pro-thrombin activity...


Why would you want samples since there are no lab tests which can monitor the therapeutic levels of the drug after administration? So for instance you can't send a patient home with Zontivity samples and have them come back to measure their INR to see if it is in the therapeutic range, or to see if the drug is working. Standard coagulation tests are not effective to measure whether or not Zontivity is working, you can only monitor the patient for adverse bleeding events resulting from using the drug, which could happen anytime (days, weeks, years) during the course of therapy, not just in the tiny sample window timeframe. In other words, you could send the patient home on samples, and just because they don't experience a major bleeding event when the samples run out, that doesn't mean they won't experience a major bleeding event next month, or later. That's not the same issue as sending a patient home with a sample of Januvia and later measuring their A1C levels to gauge effectiveness or sending a patient home with an antibiotic and waiting to see if they get a rash. With this drug, you would be sending them home with a sample and waiting to see if they start bleeding from their ears, eyes, nose or suffer a seizure indicating an intracranial hemorrhage. In the clinical trials, Zontivity increased GUSTO moderate or severe bleeding by 55%!
 




It's going ok but the label is restrictive. It's not going to be a blockbuster.

You think its a blockbuster? You are nuts! A script here a script there. Could be why they're not sure what the heck to do with it!

BTW when is Merck selling off the company or at minimum some remaining bits and pieces of this company?

Yep, think it will happen.